CPC C07K 16/2866 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6813 (2017.08); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6911 (2017.08); A61K 49/0004 (2013.01); C12N 9/93 (2013.01); G01N 33/58 (2013.01); G01N 33/60 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12Y 603/01004 (2013.01)] | 20 Claims |
1. A method of detecting a cancer in a subject in need thereof, said method comprising:
administering to said subject an antibody that specifically binds an epitope within amino acids spanning the extracellular portion of human IL-13RA2, wherein said antibody is coupled to a detectable group, in an amount effective to detect said antibody; and
detecting said detectable group, to thereby detect the cancer in the subject,
wherein said epitope is within amino acids of SEQ ID NO: 1 (Peptide 1); SEQ ID NO: 2 (Peptide 2); or SEQ ID NO: 3 (Peptide 3),
wherein said antibody comprises a variable light chain amino acid sequence of SEQ ID NO:8 or at least 95% identity thereto, and a variable heavy chain amino acid sequence of SEQ ID NO:10 or at least 95% identity thereto, and
wherein said antibody specifically binds to both human and canine IL-13RA2.
|